# Identifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistry

**Authors:** Cynthia Estrada-Zuniga, Rui Liang, Bethany Landry, Andrea Alvarez, Hector Gonzalez-Cantu, Viviane Nascimento da Conceicao, Rolando Trevino, David Gius, Sylvia Asa, James Powers, Tamara Prodanov, Anand Vaidya, Rodrigo Toledo, Jean Pierre Bayley, Debbie Cohen, Arthur Tischler, Karel Pacak, Faqian Li, Patricia Dahia

PMC · DOI: 10.21203/rs.3.rs-8553860/v1 · Research Square · 2026-01-20

## TL;DR

This study shows that high RET protein levels in tumor cells can help identify pheochromocytomas/paragangliomas caused by TMEM127 gene defects.

## Contribution

RET immunohistochemistry is proposed as a novel diagnostic tool to detect TMEM127 dysfunction in PPGLs.

## Key findings

- TMEM127-deficient tumors showed significantly higher RET expression compared to other PPGL genotypes.
- RET membrane staining had 100% specificity and 91% sensitivity for TMEM127 pathogenic variants.
- RET IHC can help distinguish non-disrupting TMEM127 variants from variants of uncertain significance.

## Abstract

Pheochromocytomas and paragangliomas (PPGLs) are rare, genetically diverse tumors originating from the adrenal medulla or extra-adrenal paraganglia, respectively. Defining a pathogenic variant is critical for patient management and family surveillance, particularly for the 35–40% of patients carrying a germline variant, including those in the TMEM127 gene. However, determining the functional impact of some variants remains challenging and requires additional testing. We recently reported that loss of TMEM127 promotes RET accumulation by reducing its degradation. Here, we evaluated RET expression by immunohistochemistry (IHC) as a potential aid to highlight TMEM127 dysfunction in PPGLs. We performed RET IHC in 104 formalin-fixed and paraffin-embedded (FFPE) sections of clinically and genetically diverse PPGLs and applied histochemical scoring (HS) for membrane (MH-S) and cytoplasm (CH-S) staining. Tumors driven by TMEM127 variants carried the highest RET expression scores (151.8 ± 62), predominantly MH-S, when compared with other PPGL genotypes, including those with RET pathogenic disruptions (69.9 ± 96.8, adjusted p = 0.04) or tumors of undefined genotype (40.8 ± 69, adjusted p = 0.0003), reflecting high specificity (100%) and sensitivity (91%). RET membrane immunoreactivity also distinguished PPGLs carrying non-disrupting TMEM127 variants from variants of uncertain significance (VUS) with likely damaging effects. These results point to high RET membrane expression as a biomarker for pathogenic TMEM127 and suggest that RET IHC may also assist in interpreting the functional impact of PPGLs carrying TMEM127 VUS.

## Linked entities

- **Genes:** TMEM127 (transmembrane protein 127) [NCBI Gene 55654], RET (ret proto-oncogene) [NCBI Gene 5979]
- **Proteins:** RET (ret proto-oncogene)
- **Diseases:** paragangliomas (MONDO:0000448)

## Full-text entities

- **Genes:** TMEM127 (transmembrane protein 127) [NCBI Gene 55654], RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}
- **Diseases:** PPGLs (MESH:D010673), Tumors (MESH:D009369)
- **Chemicals:** paraffin (MESH:D010232), formalin (MESH:D005557)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12869660/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12869660/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12869660/full.md

---
Source: https://tomesphere.com/paper/PMC12869660